Blueprint Medicines Corporation provided revenue guidance for the year 2022. The company continues to anticipate approximately $180 to $200 million in total net revenues in 2022, including approximately $115 to $130 million in AYVAKIT net product revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
107.2 USD | +0.18% | +15.26% | +16.21% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.21% | 6.73B | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2022